Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They will prioritize newer, patented therapies like Ozempic and Wegovy. The company plans to introduce these therapies in India this year. While vials will still be available, pen devices, preferred by many, may become less accessible.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bgpdvYj
via IFTTT